Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.84 |
| ▸ | NPC1 | O15118 | 14/20 | 0.84 |
| ▸ | GFER | P55789 | 3/20 | 0.84 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 9/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | TP53 | P04637 | 6/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.62 |
| ▸ | RELA | Q04206 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947174 | 0.92 | NPC1 (0.75) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL5376393 | 0.91 | RAB9A (1.00) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL15745637 | 0.91 | NPC1 (0.73) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL3288472 | 0.91 | NPC1 (0.78) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL22103857 | 0.88 | NPC1 (0.70) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL10045308 | 0.87 | NPC1 (0.68) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL2246180 | 0.87 | NPC1 (0.71) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL6924910 | 0.86 | RAB9A (0.67) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL22103728 | 0.85 | NPC1 (0.66) | RAB9ANPC1GFERRXFP1MAPT | |
| SCHEMBL3368896 | 0.85 | ESR1 (0.69) | RAB9ANPC1GFERRXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017503-A1 | TRIBENZAZOLE AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2022-01-20 | — | — | US | disclosed |
| EP-3578558-B1 | HIGHLY EFFECTIVE PHOTOPROTECTIVE AGENTS | 3V SIGMA SPA (IT) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020122359-A1 | TRIBENZAZOLE AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 랩토 | 2020-06-18 | — | — | WO | disclosed |
| EP-3578558-A1 | HIGHLY EFFECTIVE PHOTOPROTECTIVE AGENTS | 3V SIGMA S.p.A (IT) | 2019-12-11 | — | — | EP | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885GFER 4513/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885GFER 4513/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885GFER 629/4885 |
| US-20220017503-A1 | TRIBENZAZOLE AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | CYP2E1, CYP1B1, ODC1 | RAB9A 2949/4885NPC1 4030/4885GFER 958/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885GFER 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.